AMGN Bounce Up TP2 Hit · +13.6%
Biotechnology
· Bull Market
6/0 Quality
Entry
$324.79
Stop Loss
$310.05
TP1
$354.25
TP2
$368.99
R:R
2.00

Analyst vs AI Verdict

Wall Street

48.8% Buy Rating
6
Strong Buy
15
Buy
19
Hold
2
Sell
1
Strong Sell
43 analysts · April 1, 2026

AI Expert Panel

Price Chart

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) 97.9% 97.9% 97.9% 97.9% 96.2% 96.2%
P/E (TTM) 22.68 24.22 23.49 24.27 26.01 25.16
Net Margin 15.6% 19.0% 19.0% 19.0% 19.5% 19.5%
Gross Margin 70.9% 69.7% 69.7% 69.7% 72.1% 72.1%
D/E Ratio 756.65 756.65 756.65 756.65 567.49 567.49
Current Ratio 1.31 1.31 1.31 1.31 1.28 1.28

Company Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

View full stock profile →

Trade Outcome

Exit Price $368.99
Profit +13.6%
Hold Time 51 days
Max Price $374.90
Exit Reason tp2_hit

Context Synthesis

1/3 Bullish
Analysts
48.8% Buy
Insiders
Neutral
Institutions
32.28%
Earnings Beat
100.0%
Full analysis →

Historical Stats

AMGN Bounce Up

Total Attempts 2
Expired 1
Win Rate 0.0%
Last Outcome Time

Signal Info

Created Dec 16, 2025 00:00
Updated Feb 05, 2026 16:00
Market Bull
Timeout 90 days

Disclaimer: This is an automated trading signal generated by AI analysis. It is not financial advice. Always do your own research before making investment decisions. Past performance does not guarantee future results.